Shares in Ireland-based biotech Shire have zoomed up two per cent this morning after it revealed it will sell its oncology business to France's Servier for $2.4bn (£1.7bn) as it seeks to become a leader in rare disease treatment.
The deal comes as Takeda boss Christophe Weber is understood to be lining up meetings with its major holders ahead of making a potential £35bn offer for Shire.
Takeda clearly stated that strengthening its core therapeutic area of oncology (alongside gastrointestinal and neuroscience) was a key reason it wanted to gobble up Shire. The Japanese drugmaker announced in March that it was considering a bid for Shire and has until April 25 to make a formal offer or walk away under United Kingdom takeover rules.
Ornskov added that the company would consider returning the proceeds to shareholders through a share-buyback "after the current offer period regarding Takeda's possible offer concludes". Takeda declined to comment further on Monday.
"While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire's longer-term strategy", Chief Executive Officer Flemming Ornskov said in the statement.
Wholesale inflation softens marginally to 2.47% as food items turn cheaper
Wholesale prices climbed 2.47 percent year-over-year in March, nearly in line with February's 2.48 percent increase. Wholesale inflation witnessed a growth of 2.48 percent in February and 5.11 percent in March, 2017.
Silva reflects on 'most special' City title after premature birth of son
Five wins from five would give them 103 points - eclipsing Chelsea's record of 95 back in the 2004/05 season. Instead, some players had even left the country after being given a couple of days off by Guardiola.
UK's Johnson Backs Government's Decision to Strike Syria With No Parl't Approval
Government ministers were out in force over weekend to explain to government's rationale for airstrikes in Syria, with Boris Johnson leading the charge on the Andrew Marr Show .
The proceeds from the transaction, which is expected to close in this or next quarter, would "increase optionality".
Shire's board of directors started looking at offloading the oncology business in December, and said that the process considered "multiple potential strategic buyers" across Europe, Japan and the US.
Shire itself also has a track record of acquisitions, but its biggest ever deal - the $32 billion purchase of Baxalta in 2016 - was widely criticised by shareholders.
But Monday's news that Shire has sold off its cancer treatment unit - which includes its ONCASPAR (leukaemia) and ONIVYDE (pancreas) treatments - has thrown that possible takeover into doubt. In 2017, the oncology business generated $262 million in revenue.